Active Ingredient History
Anifrolumab, sold under the brand name Saphnelo, is a monoclonal antibody used for the treatment of systemic lupus erythematosus (SLE). It binds to the type I interferon receptor, blocking the activity of type I interferons such as interferon-α and interferon-β. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Lupus Erythematosus, Systemic (approved 2021)
Arthritis, Rheumatoid (Phase 2)
Healthy Volunteers (Phase 1)
Lupus Erythematosus, Systemic (Phase 3)
Lupus Nephritis (Phase 3)
Pharmacokinetics (Phase 1)
Safety (Phase 1)
Scleroderma, Systemic (Phase 1)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue